ArticleTherapeutic advances in gastroenterology2026

Final results from the vedolizumab extended access program multinational study demonstrate long-term treatment persistence and safety.

Silvio Danese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.